Effect of nabiximols on goal attainment scale scores in patients with treatment-resistant multiple sclerosis spasticity

Tools

Item Type:	Article
Title:	Effect of nabiximols on goal attainment scale scores in patients with treatment-resistant multiple sclerosis spasticity
Creators Name:	Paul, F. and Silván, C.V.
Abstract:	BACKGROUND: Nabiximols oromucosal spray (Sativex®) is an approved add-on treatment option for moderate-to-severe treatment-resistant multiple sclerosis (MS) spasticity. MATERIALS & METHODS: This prospective, observational, noninterventional, 3-month follow-up pilot study assessed the evolution of patient-selected goal attainment scale (GAS) item scores and of MS spasticity and associated symptoms during nabiximols treatment. RESULTS: In the full analysis set (n = 21), the mean (SD) overall unweighted GAS score increased from 32.1 (3.4) at baseline to 43.6 (14.6) at month 3 (p = 0.0060), constituting a clinically meaningful change. Slight improvements were observed in MS spasticity and most associated symptoms. Nabiximols improved walking ability and was well tolerated. CONCLUSION: The study provides proof-of-concept that GAS methodology can be applied to MS management in daily practice.
Keywords:	Goal Attainment Scale, Multiple Sclerosis, Nabiximols, Sativex®, Spasticity
Source:	Neurodegenerative Disease Management
ISSN:	1758-2032
Publisher:	Future Medicine
Volume:	11
Number:	2
Page Range:	143-153
Date:	1 March 2021
Official Publication:	https://doi.org/10.2217/nmt-2020-0060
PubMed:	View item in PubMed

Repository Staff Only: item control page